Business Wire

From AI Ambition to Applied Intelligence at Scale: Sia Reaches a New Milestone with Over 800 Agents in its Agent Store

14.4.2026 16:58:00 CEST | Business Wire | Press Release

Share

Sia, an international consulting group specializing in strategy, management, and AI, continues to expand its leadership in Agentic AI. Born in the digital era, the firm leverages the expertise of more than 3,000 consultants across 19 countries to help organizations scale AI-driven transformation.

Scaling Solution Intelligence: From Rapid Experimentation to Production-Ready Agentic Deployment

Following the launch of its Generative AI platform in June 2023 and its Agent Store in September 2025, Sia has reached a new milestone. With around 100 agents at launch and 400 in early 2026, the firm now offers more than 800 AI agents, available for direct consultation and deployment.

Built on a learn-by-design approach, Sia’s Agent Store enables organizations to rapidly discover, test, and scale production-ready agentic use cases across industries such as Finance, Energy, Public Sector, Healthcare, and Retail, as well as across all corporate functions.

To accelerate innovation cycles, Sia leverages rapid user interface development through advanced low-code and no-code tools from its technology partners. This approach allows teams to quickly prototype, iterate, and validate business adoption—identifying the most relevant agents from an end-user and operational perspectives.

At the same time, Sia is industrializing deployment by integrating its agents into leading market agentic infrastructures. For clients already operating within these environments, this enables a near “one-click deployment” capability, significantly reducing time-to-value.

Architects of the Agentic Journey: Bundling Business Expertise with Digital Assets to Redefine Consulting

Sia’s conviction is clear: companies don’t need more AI experimentation—they need Applied Intelligence: AI embedded into operational workflows and accountable for measurable impact. That is why the Agent Store was designed as more than a catalog—it is a platform to structure and scale Solution Intelligence.

As architects of the agentic journey, Sia’s teams help organizations define where agents create value, how they scale across operations, and how humans and AI collaborate by design.

By packaging deep business expertise into deployable agents, Sia creates a cost-effective engine for AI ROI—streamlining workflows, accelerating time-to-value, and enabling organizations to capture tangible returns from their AI investments.

This results in a new form of intervention where work is hybridized between humans and AI agents, enhancing both precision and scalability. Sia’s DNA—blending consulting expertise with proprietary digital assets—remains at the core of this transformation.

About Sia

Sia is a next-generation, global management consulting group. Founded in 1999, we were born digital. Today our strategy and management capabilities are augmented by data science, enhanced by creativity and driven by responsibility. We’re optimists for change and we help clients initiate, navigate and benefit from transformation. We believe optimism is a force multiplier, helping clients to mitigate downside and maximize opportunity. With expertise across a broad range of sectors and services, our 3,000 consultants serve clients worldwide from 48 locations in 19 countries. Our expertise delivers results. Our optimism transforms outcomes.

Visit our website and follow us on LinkedIn @Sia – Access our Agent Store - https://siagents.ai

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409310219/en/

Contacts

Press contact – press@sia-partners.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF to Release First Quarter 2026 Results on May 5, 202614.4.2026 22:15:00 CEST | Press Release

IFF (NYSE: IFF) today announced that it will release its first quarter 2026 earnings results following the market close on Tuesday, May 5, 2026. The management team will host a live webcast on Wednesday, May 6, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.business

AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release

Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im

AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release

Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im

The 2026 Japan Prize Award Ceremony Is Held With Their Majesties the Emperor and Empress of Japan in Attendance14.4.2026 19:00:00 CEST | Press Release

The Japan Prize Foundation (President: Ryozo Nagai) held an award ceremony on Tuesday, April 14, at the New National Theatre, Tokyo in Tokyo's Shibuya Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity. Cynthia Dwork, Ph.D. (USA), the winner in the field of Electronics, Information, and Communication, and Shizuo Akira, Ph.D. (Japan) and Zhijian “James” Chen, Ph.D. (USA), the winners in the field of Life Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal. The winners of the 2026 Japan Prize were recommended by approximately 16,000 prominent scientists and engineers from around the world and decided by a rigorous examination taking about 1 year. The Foundation received 107 nominations for the field of Electronics, Information,

The 2026 Japan Prize Award Ceremony Is Held With Their Majesties the Emperor and Empress of Japan in Attendance14.4.2026 19:00:00 CEST | Press Release

The Japan Prize Foundation (President: Ryozo Nagai) held an award ceremony on Tuesday, April 14, at the New National Theatre, Tokyo in Tokyo's Shibuya Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity. Cynthia Dwork, Ph.D. (USA), the winner in the field of Electronics, Information, and Communication, and Shizuo Akira, Ph.D. (Japan) and Zhijian “James” Chen, Ph.D. (USA), the winners in the field of Life Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal. The winners of the 2026 Japan Prize were recommended by approximately 16,000 prominent scientists and engineers from around the world and decided by a rigorous examination taking about 1 year. The Foundation received 107 nominations for the field of Electronics, Information,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye